Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Itm Isotope Technologies Munich SE currently manages a patent portfolio featuring 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific count indicates a highly concentrated prosecution phase where the company is likely prioritizing a core innovation. The presence of 1 pending action suggests a lean domestic filing strategy at this stage of development.
The prosecution is handled by 1 distinct examiner across 1 distinct art unit. This total alignment between the examiner and the art unit reflects a lack of technical fragmentation in the current workload. For practitioners, this means that the entirety of the company's immediate patent outcomes depends on a single relationship within the USPTO. The use of 1 distinct art unit further suggests that the technology is highly specialized within a specific subclass.
JONES, DAMERON LEVEST is identified as the busiest examiner for this portfolio, currently overseeing 1 busiest examiner pending action. Because this examiner is responsible for the company's active matter, their specific examination style and prior rulings will dictate the immediate trajectory of the intellectual property. The concentration of 1 busiest examiner pending action under a single individual simplifies the monitoring process but increases the impact of that examiner's specific tendencies.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17608921 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | JONES, DAMERON LEVEST | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17608921 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | JONES, DAMERON LEVEST | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17608921 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | JONES, DAMERON LEVEST | 1618 | §103§112 | Final Rejection | — | Pending | Nov 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialItm Isotope Technologies Munich SE has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dameron Levest Jones has the most, with 1 of Itm Isotope Technologies Munich SE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
